1. Home
  2. GRNQ vs NCEL Comparison

GRNQ vs NCEL Comparison

Compare GRNQ & NCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Greenpro Capital Corp.

GRNQ

Greenpro Capital Corp.

HOLD

Current Price

$9.26

Market Cap

23.6M

Sector

Technology

ML Signal

HOLD

NCEL

NewcelX Ltd. Ordinary Shares

HOLD

Current Price

$3.20

Market Cap

22.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GRNQ
NCEL
Founded
2013
2008
Country
Malaysia
Switzerland
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.6M
22.0M
IPO Year
2014
2019

Fundamental Metrics

Financial Performance
Metric
GRNQ
NCEL
Price
$9.26
$3.20
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
4.8K
11.8K
Earning Date
05-13-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,673,997.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
24.55
N/A
52 Week Low
$1.04
$1.83
52 Week High
$13.19
$5.12

Technical Indicators

Market Signals
Indicator
GRNQ
NCEL
Relative Strength Index (RSI) 78.06 36.73
Support Level $1.51 $3.00
Resistance Level N/A $3.21
Average True Range (ATR) 0.53 0.25
MACD 1.09 -0.05
Stochastic Oscillator 67.63 9.11

Price Performance

Historical Comparison
GRNQ
NCEL

About GRNQ Greenpro Capital Corp.

Greenpro Capital Corp operates and provides business solution services to small and medium-sized businesses located in Southeast Asia and East Asia, with a focus on Hong Kong, China, and Malaysia, and in Thailand and Taiwan. Its range of services includes cross-border business solutions, record management services, and accounting outsourcing services. Cross-border business services include other services, tax planning, trust, & wealth management. Its segments include the Service business engaged in the provision of corporate advisory & business solution services; the Real estate business segment engaged in trading or leasing of commercial real estate properties in Hong Kong & Malaysia; & the Digital business segment engaged in the provision of digital platform & trading of digital assets.

About NCEL NewcelX Ltd. Ordinary Shares

NewcelX Ltd is a clinical-stage biopharmaceutical company focused on developing transformative therapies. Built on a validated human pluripotent stem cell (hPSC) platform, the Company's main program, NCEL-101, is designed to restore functional insulin production through scalable, off-the-shelf cell replacement. It is advancing a comprehensive therapeutic approach for Type 1 Diabetes, integrating cell therapy, immune protection, and translational science, including a phase IIa clinical trial for the treatment of Amyotrophic Lateral Sclerosis (ALS) in the field of regenerative medicine, as well as the development of treatments for Central Nervous System (CNS) disorders, including Narcolepsy, utilizing its Doxa platform. Its products are Holistic, IsletRx, AstroRx, and the DOXA platform.

Share on Social Networks: